Want to see SION full AI Analyst Report?
SION Stock Chart & Stats
$45.70
$1.64(3.72%)
At close: 4:00 PM EDT
$45.70
$1.64(3.72%)
Day’s Range― - ―
52-Week Range$16.38 - $51.57
Previous CloseN/A
Volume654.94K
Average Volume (3M)433.16K
Market Cap
$2.11B
Enterprise Value$1.60K
Total Cash (Recent Filing)$216.15M
Total Debt (Recent Filing)$8.38M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 17, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding45,150,330
10 Day Avg. Volume474,586
30 Day Avg. Volume433,158
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.43Price Target Upside12.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strengthened Balance SheetThe 2025 balance sheet shows materially improved capitalization with positive equity and minimal debt, reducing refinancing risk for a development-stage biotech. This stronger capital base increases runway optionality, supports continued R&D spend, and improves negotiating leverage with partners and investors over the medium term.
Focused CFTR‑targeted R&D PipelineA clear, focused therapeutic thesis—small molecules to improve CFTR for cystic fibrosis patients, including those underserved by existing therapies—concentrates scientific effort and resources. That domain focus can accelerate learning, build domain expertise, and increase the likelihood of durable clinical progress or partnering interest if trials read out positively.
Governance And Audit ContinuityReelection of directors and ratification of Deloitte signal shareholder endorsement of the board and financial reporting framework. Stable governance and reputable audit oversight support disciplined capital allocation, credible external reporting, and smoother execution of long-term development and financing plans.
Bears Say
Pre‑revenue With Widening Operating LossesThe company remains pre-revenue while operating losses have more than doubled over several years, reflecting escalating R&D and development costs. Without product revenue, ongoing losses materially constrain the firm's ability to self-fund future development and make long-term value creation contingent on successful clinical outcomes or external financing.
Persistent, Rising Cash BurnOperating and free cash flow are deeply negative and have worsened, indicating substantial and persistent cash consumption. While cash burn tracks reported losses (implying limited noncash distortion), the sustained outflows create structural financing needs that can pressure dilution, strategic flexibility, and the timing of development programs.
Ongoing Reliance On External FundingEven with a stronger 2025 equity base, the company is development-stage and explicitly reliant on external capital until revenues begin. This structural dependence exposes the firm to capital‑market conditions, potential dilution from future raises, and timing risk for trial readouts that determine the ability to secure favorable financing or partnerships.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $16.38 and its highest was $51.56 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $2.11B.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 16 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.514 by -$0.086.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.65.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 45,150,330 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.514. Following the earnings report the stock price went down -10.903%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.43 (12.53% Upside)
$51.43 (12.53% Upside)
Blogger Sentiment
Bullish
SION Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 527.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.48%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$51.43
▲(12.53% Upside)
Technical Analysis
Sarepta Therapeutics
―
Intellia Therapeutics
―
Stoke Therapeutics
―
Beam Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
33.61% Insiders
9.60% Mutual Funds
0.13% Other Institutional Investors
49.53% Public Companies and
Individual Investors